Prevalence and prognosis of hypoxia‐inducible factor‐2α ( HIF ‐2α) pathway gene mutations across advanced solid tumors
Cancer Medicine · 2024
DOI: 10.1002/cam4.7358 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Cancer Medicine, 2024. Verfasst von Wenjun Zhong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Merck & Co., Inc., Rahway, New Jersey, USA. Hauptthemen laut MEDLINE: Basic Helix-Loop-Helix Proteins, Neoplasms, Mutation. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Abstract (Originalsprache)
Introduction
Hypoxia‐inducible factor‐2α (HIF‐2α) modulates the hypoxic response pathway in tumors; however, mutations in pathways (including SDHA, SDHB, SDHC, SDHD, FH, and VHL genes) that are suspected to activate HIF‐2α are poorly understood, with limited understanding of the prevalence and clinical prognosis.
Methods
This retrospective observational study used a de‐identified nationwide (US‐based) clinico‐genomic database (CGDB) across 15 available tumor types.
Results
Among the 9467 adult patients with advanced/metastatic solid tumors included in the analysis, any mutation at the above‐mentioned six genes was observed in 1.8% (95% CI: 1.5–2.1) of patients. The mutation prevalence ranged from 0.05% of SDHD to 0.93% of VHL. When further stratified by tumor type, the prevalence of gene mutation in each tumor type was well below 1%, except for VHL with 44% in renal cell carcinomas (RCC). Excluding RCC, the prevalence of any HIF‐2α gene mutations in the study population was 0.9% (95% CI: 0.8–1.2). The median overall survival (OS) from 1 and 2 L therapy among patients with any HIF‐2α gene mutation was 14.5 (95% CI: 11.5–24.2) and 9.3 (95% CI: 6.0–18.1) months, respectively, compared with 13.4 (95% CI: 12.9–13.9) and 9.8 (95% CI: 9.3–10.4) months among patients without HIF‐2α gene mutations. Discussion and Conclusions The prevalence of HIF‐2α related gene mutations was generally low (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Merck & Co., Inc., Rahway, New Jersey, USA.
ORCID-Profile: Wenjun Zhong, Changxia Shao
Förderung
- Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
Zitieren
APA
Zhong, W., Ma, J., Chen, C., Dettman, E. J., Cristescu, R., Naik, G. S., Jin, F., & Shao, C. (2024). Prevalence and prognosis of hypoxia‐inducible factor‐2α ( HIF ‐2α) pathway gene mutations across advanced solid tumors. Cancer Medicine. https://doi.org/10.1002/cam4.7358
Vancouver
Zhong W, Ma J, Chen C, Dettman EJ, Cristescu R, Naik GS, et al. Prevalence and prognosis of hypoxia‐inducible factor‐2α ( HIF ‐2α) pathway gene mutations across advanced solid tumors. Cancer Medicine. 2024. doi:10.1002/cam4.7358
BibTeX
@article{Zhong2024,
author = {Zhong, Wenjun and Ma, Jiemin and Chen, Cai and Dettman, E J and Cristescu, Razvan and Naik, Girish S and Jin, Fan and Shao, Changxia},
title = {Prevalence and prognosis of hypoxia‐inducible factor‐2α ( HIF ‐2α) pathway gene mutations across advanced solid tumors},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.7358}
}
EUVIMED